Skip to main content
. 2018 Sep 27;5(6):1165–1172. doi: 10.1002/ehf2.12352

Table 2.

Characteristics of patients with changed and unchanged preferences for life‐sustaining treatments

Characteristics Unchanged group (n = 63) Changed group (n = 36) P value
Age (years) 77 ± 12 73 ± 16 0.209
Male, n (%) 30 (47.6) 22 (61.1) 0.196
Systolic blood pressure (mmHg) 127 ± 35 117 ± 24 0.145
Prior heart failure admissions, n (%) 40 (63.5) 22 (61.1) 0.814
LVEF (%)a 48.5 ± 18.5 44.5 ± 18.2 0.375
ADHERE risk score (low/intermediate/high), n (%) 21/40/2 13/21/2 0.790
(33.3)/(63.5)/(3.2) (36.1)/(58.3)/(5.6)
Ischaemic heart disease, n (%) 24 (38.1) 11 (30.6) 0.450
Co‐morbidities
Hypertension, n (%) 31 (49.2) 15 (41.7) 0.469
Diabetes, n (%) 20 (31.7) 17 (47.2) 0.126
Atrial fibrillation, n (%) 22 (34.9) 16 (44.4) 0.349
Cerebrovascular disease, n (%) 10 (15.9) 8 (22.2) 0.431
Malignancy, n (%) 9 (14.3) 8 (22.2) 0.314
Laboratory value on admission
Sodium (mmol/L) 137.4 ± 5.4 136.7 ± 4.8 0.554
BUN (mg/dL) 50.3 ± 30.0 55.4 ± 46.1 0.557
Creatinine (mg/dL) 2.2 ± 1.7 2.0 ± 1.6 0.467
BNP (pg/mL)b 1573 ± 1299 1301 ± 1454 0.363
In‐hospital treatments
ACE‐I/ARB, n (%) 30 (47.6) 21 (58.3) 0.305
Beta‐blockers, n (%) 31 (49.2) 11 (30.6) 0.071
Intravenous inotropy, n (%) 42 (66.7) 26 (72.2) 0.566
Intubation and MV, n (%) 21(33.3) 12 (33.3) 1.000
IABP/PCPS, n (%) 5 (7.9) 2 (5.6) 1.000
Renal replacement therapy, n (%) 6 (9.5) 5 (13.9) 0.506
Cardiopulmonary resuscitation, n (%) 14 (22.2) 0 (0.0) 0.002
End‐of‐life conversations
The number of conversations (times) 1.7 ± 1.2 2.9 ± 1.5 <0.001
Days from initial conversation to death (days) 19 ± 36 38 ± 58 0.075
Nurse's participation in the conversations, n (%) 30 (47.6) 16 (44.4) 0.761
Surrogate decision maker
Male, n (%) 36 (57.1) 12 (33.3) 0.023
Child, n (%) 38 (60.3) 20 (55.6) 0.676
Spouse, n (%) 19 (30.2) 15 (41.7) 0.276
Hospital stay (days) 45 ± 50 58 ± 66 0.319
Cardiac cause death, n (%) 42 (66.7) 29 (80.6) 0.140

Date are presented as mean ± standard deviation. Abbreviations are given in Table 1.

a

Available data for 75 patients.

b

Available data for 91 patients.